Setmelanotide

Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. It is grouped under the following drug class(es): MC4 receptor agonists and Peptides. Its therapeutic use is listed as weight loss agents. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinamide, cyclic (2-8)-disulfide, Setmelanotidum and Imcivree. Its PubChem CID is 11993702.

CAS No 920014-72-8
Molecular Formula C49H68N18O9S2
Molecular Weight 1117.3 g/mol
Synonyms (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide

Frequently Asked Questions